Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Jun 1;15(6):e0234147. doi: 10.1371/journal.pone.0234147

Enhanced phosphorylation of PERK in primary cultured neurons as an autonomous neuronal response to prion infection

Misaki Tanaka 1, Takeshi Yamasaki 1,¤, Rie Hasebe 1,¤, Akio Suzuki 1, Motohiro Horiuchi 1,2,*
Editor: Roberto Chiesa3
PMCID: PMC7263615  PMID: 32479530

Abstract

Conversion of cellular prion protein (PrPC) into the pathogenic isoform of prion protein (PrPSc) in neurons is one of the key pathophysiological events in prion diseases. However, the molecular mechanism of neurodegeneration in prion diseases has yet to be fully elucidated because of a lack of suitable experimental models for analyzing neuron-autonomous responses to prion infection. In the present study, we used neuron-enriched primary cultures of cortical and thalamic mouse neurons to analyze autonomous neuronal responses to prion infection. PrPSc levels in neurons increased over the time after prion infection; however, no obvious neuronal losses or neurite alterations were observed. Interestingly, a finer analysis of individual neurons co-stained with PrPSc and phosphorylated protein kinase RNA-activated-like endoplasmic reticulum (ER) kinase (p-PERK), the early cellular response of the PERK-eukaryotic initiation factor 2 (eIF2α) pathway, demonstrated a positive correlation between the number of PrPSc granular stains and p-PERK granular stains, in cortical neurons at 21 dpi. Although the phosphorylation of PERK was enhanced in prion-infected cortical neurons, there was no sign of subsequent translational repression of synaptic protein synthesis or activations of downstream unfolded protein response (UPR) in the PERK-eIF2α pathway. These results suggest that PrPSc production in neurons induces ER stress in a neuron-autonomous manner; however, it does not fully activate UPR in prion-infected neurons. Our findings provide insights into the autonomous neuronal responses to prion propagation and the involvement of neuron-non-autonomous factor(s) in the mechanisms of neurodegeneration in prion diseases.

Introduction

Prion diseases are a group of fatal neurodegenerative disorders in animals and humans, such as scrapie in sheep and goats, bovine spongiform encephalopathy, chronic wasting disease in cervids, and Creutzfeldt-Jakob disease (CJD) in humans. The presence of misfolded prion protein (PrP), designated as PrPSc, in the central nervous system is a distinct feature of prion diseases. Activation of microglia and astrocytes, which is often observed long before the clinical onset, is also a pathological hallmark of prion disease and is thought to be involved in its neuropathogenesis [1, 2]. In prion-infected mice, early synaptic dysfunction correlates with behavioral abnormalities, which precede histopathological alterations, including neuronal loss and the characteristic spongiform changes in neuropils [3, 4].

PrPSc is a pathogenic and conformational isoform of cellular prion protein (PrPC), which is encoded by the host gene Prnp. Since PrP-deficient mice are resistant to prion infection, PrPC is a key molecule in the pathogenesis of the prion diseases [5, 6]. Given the fact that PrP-deficient brain tissue is not damaged by exogenous PrPSc produced in PrP-expressing tissue grafts nearby [7], and conditional knockout of the neuronal Prnp protects mice from prion disease [8, 9], the intraneuronal formation of PrPSc seems requisite for prion pathogenesis. Therefore, it should be a top priority to identify the neuronal responses to prion propagation and to elucidate the mechanisms of neurodegeneration in prion diseases; as currently, a detailed mechanism is unclear. Mice inoculated with prions have been used for models of prion diseases as they reproduce the process of neurodegeneration that occurs during prion diseases in humans and animals. However, the presence of activated glial cells hampers the analysis of autonomous neuronal responses to prion propagation in neurons. Thus, neuronal cultures or ex vivo systems are required for finer analyses of the autonomous neuronal events that take place in response to PrPSc formation. The use of immortalized neural cell lines are one option; however, only a few cell lines are capable of stable and consistent prion propagation [10, 11]. Unfortunately, these prion-susceptible cell lines show no sign of cytotoxicity as a consequence of persistent prion infection except for a single report using the GT1 hypothalamic cell line [12].

Primary neuronal cultures are thought to be useful ex vivo tools for the analysis of prion-induced neurodegeneration mechanisms [1315]. Cronier et al. reported that primary cultures of cerebellar granule neurons (CGNs) from transgenic mice expressing ovine PrP with an astrocyte feeder layer have increased ratios of apoptosis when exposed to sheep scrapie agent [16]. In addition, Hannaoui et al. reported that decreases in microtubule-associated protein 2 (MAP2)-positive neuronal population occurred in murine CGNs, striatal, and cortical primary neurons after exposure to mouse-adapted scrapie prions. However, these primary neuronal cultures comprise not only neurons, but also glial fibrillary acidic protein (GFAP)-positive astrocytes that can account for up to 30% of the total cells [17]. This prompted us to use a neuron-enriched primary cerebral cortical culture in which the growth of astrocytes is minimized by anti-mitotic agent treatment. These primary cortical neurons are susceptible to mouse-adapted scrapie prions and produced PrPSc similar to that in brains; neuronal PrPSc localizes to cell surfaces and neurites, rather than intracellular vesicles, and also possesses its N-terminus [18]. In addition to cortical neurons, in the current study, we examined thalamic neurons which allow us to address possible differences in the vulnerability of neurons derived from different brain regions to prion propagation.

The involvement of unfolded protein response (UPR) has been suggested as one of the mechanisms for prion-induced neurodegeneration. UPR is an elaborate set of cellular responses to misfolded proteins overloading the endoplasmic reticulum (ER) [19], and is implicated in the pathophysiology of various protein misfolding diseases [20]. Of the three well-identified initial signal transducers of UPR, protein kinase RNA-activated-like ER kinase (PERK) is activated via autophosphorylation of a cytoplasmic domain when a luminal sensor domain detects ER stress. PERK then phosphorylates the α-subunit of eukaryotic initiation factor 2 (eIF2α), blocking its function in the 43S-translation-initiation complex, resulting in repression of global protein synthesis [21, 22]. Conversely, during ER stress, activating transcription factor 4 (ATF4) is selectively translated and upregulates stress-responsive genes such as ATF3 (Atf3) [23], DNA damage-induced protein 34 kDa (GADD34/Ppp1r15A) [24], and the pro-apoptotic C/EBP homologous protein (CHOP/Ddit3) [24, 25]. While GADD34 plays a role in the negative feedback to dephosphorylate eIF2α, CHOP sensitizes cells that cannot keep up with persistent ER stress for cell death by down-regulating the anti-apoptotic protein Bcl-2, and by perturbation of cellular redox systems [26, 27]. With regard to the pathogenesis of prion diseases, upregulation of ER chaperones and enzymes such as Grp58, Grp78, and Grp94, which indicates the induction of UPR, has been reported in the brain of patients with sporadic and variant CJD, as well as prion-infected mice [28, 29]. Moreno et al. reported the involvement of PERK-eIF2α pathway during neurodegeneration in prion diseases; overexpression of GADD34, which reduced the phosphorylation levels of eIF2α, rescued mice from disease progress. Conversely, inhibition of eIF2α dephosphorylation exacerbated neurotoxicity in prion-infected mice [30, 31]. It is still an open question as to whether production of PrPSc in neurons directly induces ER stress, and if it does, whether neuronal PrPSc activates neurotoxic signaling pathways downstream of the PERK-eIF2α pathway.

In the present study, we analyzed the consequences of autonomous neuronal responses on prion propagation using neuron-enriched cortical and thalamic primary cultures. Although no apparent neuronal loss or neurite loss was associated with the continuous production of PrPSc in the primary neurons, we found that phosphorylation of PERK was enhanced in prion-infected cortical neurons in accordance with the amount of PrPSc in a cell. Interestingly, this did not fully activate the down stream pathway of UPR.

Materials & methods

Antibodies

For PrPSc-specific detection in immunofluorescence assay (IFA), mouse monoclonal antibodies (mAbs) 132 and 8D5 that recognize mouse PrP amino acids 119–127 [32] and 31–39 [33], were used. Anti-PrP mAb 31C6 that recognizes mouse PrP amino acids 143–149 [32] was used to detect proteinase K-resistant PrP (PrP-res) by immunoblotting. Other commercially available antibodies used for IFA and immunoblotting are listed in Table 1.

Table 1. Commercially available antibodies used in this study.

Antigen Host poly/mono Clone Manufacturer Product No.
ATF4 Rabbit mAb D4B8 CST #11815
Beta-III tubulin rabbit pAb abcam ab18207
Bip Rabbit pAb abcam ab21685
CHOP Rabbit mAb D46F1 CST #5554
eIF2-alpha Rabbit mAb D7D3 CST #5324
GluR1(AMPA subtype) rabbit pAb abcam ab31232
microtubule-associated protein 2 (MAP2) Chicken pAb abcam ab5392
NeuN rabbit mAb EPR12763 abcam ab177487
NMDAR1 rabbit mAb EPR2481(2) abcam ab109182
p-EIF2S1(S51) Rabbit mAb E90 abcam ab32157
PERK Rabbit mAb C33E10 CSTa #3192
p-PERK(Thr980) Rabbit mAb 16F8 CST #3179
PSD95 mouse mAb 7E3-1B8 abcam ab13552
SAP102 rabbit pAb abcam ab152132
SNAP25 rabbit pAb abcam ab5666
synaptophysin rabbit mAb EP1098Y abcam ab52636
syntaxin1a rabbit pAb abcam ab41453
VAMP2 rabbit pAb abcam ab3347

a) Cell Signaling Technology

Preparation of neuron-enriched primary cultures

All of the procedures for animal experiments were conducted in accordance with protocols approved by the Institutional Committee for Animal Experiments at Hokkaido University (approval No. 18–0110, approved until end March 2020). Hokkaido University provides the training for animal care and use twice a year. The animal care and use program at Faculty of Veterinary Medicine, Hokkaido University, has been accredited by AAALAC International since 2008. Primary cortical and thalamic neurons were prepared from ICR mouse embryos of embryonic day 14 (pregnant mice were purchased from Japan Clea Inc.) as described previously [18]. Pregnant mice were sacrificed under the anesthesia with Sevoflurane and embryos were recovered and cerebral cortices and thalami were collected from embryonic brains. Thirty pregnant ICR mice were used in this study. For neuron-enrichment, meninges were carefully removed and cells were treated with AraC (Sigma-Aldrich) at a final concentration of 0.25 μM from 4 to 7 days in vitro (div). At 7 div, microsomal fractions that were prepared from brains of terminally ill mice infected with mouse-adapted scrapie Chandler and Obihiro strains were inoculated into cultures at an amount equivalent to 5 ng of PrP-res per 105 cells. Inoculum prepared from brains of age-matched healthy mice was used for mock-infection. At 4 days post infection (dpi), the media were completely replaced with fresh media without AraC. In some experiments, uninfected neurons were treated with tunicamycin (Sigma-Aldrich) at a final concentration of 5 μg/ml for 24 hr just before the experiments to induce ER stress and UPR.

Immunoblot analysis

Primary neurons were lysed with lysis buffer [34] and protein concentrations were measured with a DC protein assay (Bio-Rad). Cell lysates were subjected to SDS-PAGE on 8% or 15% polyacrylamide gels. For immunoblot analysis of UPR-related proteins, neurons were directly lysed in SDS-sample buffer containing a cOmplete protein inhibitor cocktail and a PhosSTOP phosphatase inhibitor cocktail (Roche). Proteins were transferred to polyvinylidene difluoride membranes and the blots were probed with appropriate antibodies followed by chemiluminescence detection as previously described [34]. βIII-tubulin staining was used as an internal marker for normalization.

Immunoblotting for PrP-res

Proteinase K digestions were carried out using 30 μg of total protein from each lysate with 20 ug of proteinase K for 10 min at 37°C. SDS-PAGE, immunoblotting, and chemiluminescence detection were performed as previously described [34, 35]. PrP-res was detected by direct immunostaining with Fab fractions of mAb 31C6 that were genetically conjugated with human placental alkaline phosphatase [36].

Immunofluorescence staining of primary neurons

Immunostaining of primary neurons was performed as previously described [18, 37]. Briefly, neurons were fixed with 4% paraformaldehyde-PBS and permeabilized with 0.1% TritonX-100 in PBS. For PrPSc-specific staining with mAb 132, cells were treated with 5 M guanidine thiocyanate (GdnSCN) at RT for 10 minutes, while GdnSCN treatment was omitted for PrPSc-specific staining with mAb 8D5. After blocking with 5% fetal bovine serum-PBS, cells were incubated with primary antibodies at 4°C overnight. Appropriate second antibodies conjugated with Alexa Fluor dyes (Molecular Probes) were selected for each experiment, and nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI). A LSM700 inverted confocal microscope and ZEN2009 software (ZEISS) were used for image acquisition, except for the experiments in Fig 2 described in the next section.

Fig 2. Influence of prion propagation on the density of neuronal cells and neurites.

Fig 2

Neuronal cell density and neurite density of CxNs (A) and ThNs (B) were measured by immunofluorescence assay followed by image analysis using MetaMorph software. Cell density and neurite density were defined as the number of NeuN-positive nuclei per 0.01 mm2 and the surface coverage (%) by MAP2-positive neurites, respectively, which are represented as relative values to the averages of corresponding mock-infected neurons at each dpi (mean ± SD of nine replicates from three independent experiments). *, p < 0.05 by Dunnett’s test using mock-infected neurons as control groups.

Image analysis of cell density and neurite outgrowth

Neurons cultured on ibidi μ-plates were immunostained for NeuN and MAP2 with DAPI counterstaining as described above. Images were acquired at 9 fixed positions in each well configured by XY-coordinates prior to experiment (in total 1.36×106 μm2 from one well) using an Olympus IX71 fluorescence microscope with ×10 objective lens operated by MetaMorph software version 7.8.4.0 (Molecular Devices) using multiple stage positions and auto focus functions. MetaMorph was also used for image analyses. Living neuronal nuclei were identified as DAPI-positive objects whose size was ≥ 60 μm2 and average NeuN intensities that were above a threshold. We used the same threshold for both mock-infected and prion-infected preparations in each experiment. Neurite density was measured using a threshold function and was represented as the surface coverage (%) by MAP2-positive area. In these measurements, an average of the 9 positions was acquired to calculate a representative score of the well, and 9 wells from 3 independent experiments were used for each group.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Neurons cultured on 12-well plates were directly dissolved into TRIzol reagent (Invitrogen) and total RNA was isolated according to the manufacturer’s instructions. RNA was resuspended into nuclease-free water (Invitrogen), and the concentration was determined using a Nano Drop spectrometer (Thermo Scientific). cDNA was synthesized from 300–600 ng of total RNA using First-Strand cDNA Synthesis kit (GE Healthcare) with pd(N)6 primer. Quantitative PCR was carried out using TaqMan Fast Universal PCR Mater Mix and TaqMan Probes (Applied Biosystems) on a 7900HT Fast Real-Time PCR system (Applied Biosystems). The TaqMan Probes used in this analysis are listed in Table 2. Data was analyzed by delta-delta cycle threshold method using Tubb3 (βIII-tubulin) as an internal control.

Table 2. Commercially available TaqMan Probes used in this study.

Target gene Product No. Target gene Product No.
Atf3 Mm00476033_m1 Ppp1r15A Mm01205601_g1
Ddit3 Mm01135937_g1 Snap25 Mm01276449_m1
Dlg4 Mm00492193_m1 Stx1a Mm00444008_m1
Gria1 Mm00433753_m1 Syp Mm00436850_m1
Hspa5 Mm00517691_m1 Tubb3 Mm00727586_s1

Preparation of recombinant adeno-associated viral vector (rAAV)

To visualize neurons in primary cultures, we used a rAAV expressing enhanced green fluorescence protein (EGFP) under the control of the human synapsin promoter. rAAV was prepared as described by Challis et al. [38] with slight modifications. Briefly, the viral genome was packaged into AAV-PHP.eB capsid by triple-transfection of HEK293T cells with three plasmids; pAAV-hSyn-EGFP was a gift from Bryan Roth (Addgene, plasmid #50465), pUCmini-iCAP-PHP.eB was a gift from Viviana Gradinaru (Addgene, plasmid #103005) [39], and pHelper vector in AAVpro® CRISPR/SaCas9 Helper Free System (AAV2) (Takara Bio). rAAV-PHP.eB-hSyn-EGFP was purified by iodixanol-density gradient centrifugation using a the SW32 Ti rotor at 175,000g (32,000 rpm) for 6.5 hr at 18°C followed by ultrafiltration using Amicon Ultra-15 Ultracel-100K columns (Merck Millipore). Titration of rAAV was performed using quantitative PCR. To prepare the viral DNA sample, rAAV was digested with PK at 50 μg/ml at 50°C overnight. PK digestion was stopped by adding Pefabloc SC (Roche) at a final concentration of 2.2 mM and boiling for 20 min. Quantitative PCR was carried out using a custom-designed TaqMan Probe targeting the woodchuck hepatitis posttranscriptional regulatory element sequence with TaqMan Fast Universal PCR Mater Mix (Applied Biosystems). Linearized pAAV-hSyn-EGFP (5,265 base pairs) with PvuI digestion was used as the DNA standard. Of note, 10 ng of the linearized dsDNA fragments correspond to 7.4 × 109 ssDNA molecules.

Quantification of the signal frequency of phosphorylated PERK (p-PERK)

Z-series of confocal images (z-stack) from the bottom to the top of cell bodies of neurons immunostained for p-PERK, MAP2, and PrPSc (with mAb 8D5) were acquired at 0.78 μm steps with a ×630 final magnification. The z-stacks were reconstructed by 3D rendering to build segmented objects designated as “surface” using the Surface function of Imaris software version 7.6.1. (Bitplane). MAP2-surface (cell bodies), DAPI-surface (nuclei), mAb 8D5-surface (PrPSc), and p-PERK-surface (p-PERK granules) were reconstructed. Neurites were manually pruned away to separate individual neurons. The number of p-PERK surfaces inside the cell body (MAP2 surface) but outside the nucleus (DAPI surface) of each neuron was counted and represented as the signal frequency (granule/cell). The number of PrPSc surfaces inside or adherent to the cell body was also counted, which was used to classify prion-infected neurons into three subpopulations according to the amount of PrPSc as described in Fig 5.

Fig 5. Phosphorylation of PERK in PrPSc-positive neurons.

Fig 5

(A) Multiple immunofluorescence staining for p-PERK and PrPSc with counter staining for MAP2 and nuclei (DAPI) in CxNs at 21 dpi. PrPSc was stained with mAb 8D5. Figures are shown as maximum intensity projection images created from z-series stacks of confocal images at ×630 final magnification. Arrows, PrPSc++ neurons. Bar, 10 μm. (B, C) Quantification of p-PERK and PrPSc in individual neurons by 3D-image analysis using Imaris software. Each dot in the scatter diagram (B) represents an individual neuron (r, correlation coefficient). In (C), Obihiro-infected CxNs were analyzed as a whole (Obihiro) and as three subpopulations classified by the frequency of PrPSc signals at the soma. The definition of the three subpopulations and the number of cells used for this analysis is as follows: PrPSc_low (< 4 PrPSc signals/cell, n = 19), PrPSc+ (≥ 4 PrPSc signals/cell, n = 29, including PrPSc++), and PrPSc++ (≥ 18 PrPSc signals/cell, n = 16). The number of cells in mock-infected CxNs and Obihiro-infected CxNs used for the analysis are n = 35 and n = 48 (the total of PrPSc_low and PrPSc+ subpopulations), respectively. Differences between the groups were analyzed by Steel-Dwass’s multiple comparison tests (*, p < 0.05; **, p < 0.01). (D) Co-immunofluorescence staining for ATF4 and PrPSc with counter staining for MAP2 and nuclei (DAPI) in CxNs at 21 dpi. PrPSc was stained with mAb8D5. Uninfected neurons treated with tunicamycin were used as a positive control for ATF4-staining. The green fluorescence in mock- and Obihiro-infected CxNs is the autofluorescence from the condensed nuclei of dead cells. Arrows, PrPSc++ neurons. Bar, 50 μm.

Quantification of the density of synaptic terminals

Neurons transduced with the rAAV vector expressing EGFP were immunostained for PrPSc (with mAb 8D5) and PSD95 or synaptophysin. For the double staining of PrPSc with PSD95, the immunostaining procedure was slightly modified since both of the antibodies are mouse IgGs. First, immunostaining for PSD95 was completed by indirect method, then free Fab regions of the anti-mouse IgG secondary antibodies were blocked with a mouse IgG isotype control antibody to avoid cross-reaction with mAb 8D5. Alexa Fluor 555-conjugated mAb 8D5 was used for the PrPSc-specific immunostaining [18]. Z-stacks of EGFP-expressing neurons were acquired from the bottom to the top of neurites at 0.78 μm steps with a 63× objective lens and 0.5× digital zoom, which allowed us to obtain images with a 203 μm × 203 μm at ×315 final magnification. The surfaces of signals from EGFP (neurons), DAPI (nuclei), mAb 8D5 (PrPSc) and PSD95- or synaptophysin-positive granules (post- or pre-synaptic terminals), were reconstructed using Imaris software. The number of PSD95 or synaptophysin surfaces inside EGFP surfaces were counted and divided by the volume of each EGFP surface to represent the densities of post- and pre-synaptic terminals for each neuron (number of terminals/cell volume of 1000 voxels). The number of PrPSc surfaces was also counted as described above.

Results

Prion propagation in primary cultures of mouse cerebral cortical and thalamic neurons

We previously reported that primarily cerebral cortical neuronal cultures (CxN) of ICR mouse embryos propagated mouse-adapted scrapie prions (22L, Chandler, and Obihiro strains) [18]. In the current study, we prepared primary neurons from thalamus (ThN) as well as the cortex by considering any differences in the efficiency of prion propagation ex vivo. To analyze autonomous neuronal events triggered by PrPSc production in neurons, primary cultures were briefly treated with AraC to suppress glial cells growth (hereafter referred to as neuron-enrichment). Proportion of neuronal cells in primary cultures were shown in S1 Fig. NeuN-positive, GFAP-positive, and NeuN- and GFAP-double negative cells were 89.3%, 3.5%, and 7.2%, respectively in AraC treated, mock-infected CxN. GFAP-positive cells were 13.8% in CxN without AraC treatment, indicating successful reduction of astrocyte growth in our CxN. Similar tendency was observed in ThN. Immunoblotting showed linear increases in PrP-res from 7 days post infection (dpi) to 28 dpi, in CxNs and ThNs exposed to Chandler and Obihiro prions, demonstrating successful prion propagations. As expected, we did not detect PrP-res in mock-infected neurons (Fig 1A and 1B). PrP-res levels in CxNs were equivalent to those in ThNs for both prion strains tested at 21 dpi (Fig 1C). The level of PrP-res in Obhiro-infected neurons appeared to be higher than that in Chandler-infected neurons; however, this is probably due to difference in intrinsic PK-resistance of PrPSc in each prion strain [40]. PrPSc-specific immunostaining with mAb 132 displayed PrPSc clinging to neuronal cell bodies and neurites in prion-infected CxNs and ThNs (Fig 1D). The frequencies of PrPSc-positive neurons (Fig 1D, filled arrowheads) in Obihiro-infected CxN and ThN were 42.9% and 54.8%, respectively, when examined at 200× final magnification (21 dpi). Notably, some PrPSc-positive neurons possessed a swarm of filamentous PrPSc staining around their cell bodies and neurites (fPrPSc neurons, Fig 1D). fPrPSc neurons accounted for 10.0% and 7.5% of the total neurons in Obihiro-infected CxN and ThN (21 dpi), respectively.

Fig 1. Prion propagation in primary cultures of mouse cerebral cortical and thalamic neurons.

Fig 1

(A, B) Representative immunoblots for PK-resistant PrPSc (PrP-res) in (A) cerebral cortical neurons (CxN) and (B) thalamic neurons (ThN), infected with mouse-adapted scrapie Chandler and Obihiro strains. Graphs show the results of quantification as a mean ± SE of three independent experiments performed in triplicate. Mean intensities at 7 dpi were used as benchmarks (100%) for time-course comparisons in order to show rate of prion propagation (detected as PrP-res) after the establishment of prion infection in the primary neurons: dpi, days post infection; M, mock-infected neurons at 28 dpi. (C) Comparison of PrP-res levels between neuronal types or prion strains at 21 dpi. The graph shows the mean ± SD for experiments performed in triplicate. (D) Immunofluorescent detection of PrPSc in primary neurons at 21 dpi. Cells were denatured with guanidine thiocyanate but not digested with PK for PrPSc-specific detection by mAb132. Panels labeled fPrPSc show neurons with a swarm of typical filamentous PrPSc staining. Filled arrowheads, neurons with PrPSc staining (PrPSc-positive neurons); open arrowheads, neurons with apparently no PrPSc staining. Figures are shown as maximum intensity projection images created from z-stack confocal sections at ×315 final magnification. Bars, 20 μm.

Influence of prion propagation on the densities of neuronal cells and neurites

CxN and ThN successfully propagated Chandler and Obihiro prions (Fig 1). Thus, we examined whether production of PrPSc could cause any immediate alteration in CxN and ThN. Microtubule-associated protein 2, MAP2, is mainly distributed over the dendrites and cell bodies of mature neurons and is widely used as a neuronal marker. NeuN is an alternative splicing factor of pre-mRNAs named Rbfox3, and is also a reliable marker for mature neurons. Since NeuN is detected in neuronal nuclei and disappears when cells die, immunostaining for NeuN is a convenient way for counting live neurons in primary culture where dead cell populations are inevitable over time. We immunostained for MAP2 and NeuN, followed by quantitative image analysis to evaluate the number of neurons and their density of neurites in CxN and ThN. As shown in S1 Fig, there were time-dependent changes in the number of NeuN-positive cells and MAP2-positive neurite extensions; CxN grew slowly and displayed the highest densities of neuronal cells at 14 dpi followed by continued elaboration into a dense neurite network, whereas ThN had the highest densities of both neuronal cells and neurites at 7 dpi. Taking into consideration experimental variations that exist between independently prepared primary neuronal cultures, measurements was normalized to the average of mock-treated neurons in the same experiment at each time point. Neuronal cell density was lower in prion-infected CxNs than in mock-infected CxN at 7 dpi, however, the decreasing trends were not continuous (Fig 2A); in fact, the density of neuronal cells in prion-infected CxNs were comparable to mock-infected CxN at 21 dpi when 42.9% of cells were positive for PrPSc in Obihiro-infected CxN. Neurite densities of prion-infected CxNs were slightly lower than those of mock-infected CxN at all experimental timepoints, but neurodegenerative alterations, such as exacerbation of neurite sparseness, were not observed despite the rising levels of PrP-res (Fig 2A). In prion-infected ThNs, the number of neurons decreased to approximately 70% of mock-infected ThN by 14 dpi, implying the existence of subpopulation(s) that are more susceptible to acute prion toxicity [15, 41] ex vivo (Fig 2B). However, prion-infected ThNs did not show progressive neuronal loss despite continuous increases in PrP-res levels. Moreover, prion-infected ThNs maintained dense neurite-networks comparable to mock-infected ThNs throughout the experiment (Fig 2B), suggesting that the production of PrPSc did not solely induce neuronal death nor neurite loss detectable by immunostaining for MAP2 and NeuN.

ER stress and UPR in prion-infected neurons

The PERK-eIF2α pathway of UPR copes with disrupted proteostasis by restraining global protein synthesis via phosphorylation of PERK and eIF2α; reducing ER tasks and enabling cells time to refold or dispose of inaccurately synthesized proteins [19]. ATF4 is a key molecule in this pathway as it induces effector molecule production, including the pro-apoptotic protein CHOP [42]. The involvement of ER stress and the PERK-eIF2α pathway in prion pathogenesis has been demonstrated in prion-infected mice [30, 31], though it is still unclear whether prion propagation directly evokes ER stress and induces UPR in neurons. To examine the activation state of UPR during the continuous production of PrPSc in CxN and ThN, we first analyzed phosphorylation levels of PERK and eIF2α, and the induction of ATF4 in Obihiro-infected neurons. Immunoblotting revealed that enhanced phosphorylation of PERK in prion-infected CxNs at 7 dpi and thereafter. The prion-infected CxNs also had a tendency to increase the phosphorylation level of eIF2α, although it was not statistically significant (Fig 3A and 3C). On the other hand, phosphorylation levels of PERK and eIF2α in Obihiro-infected ThN were comparable to those of uninfected ThN (Fig 3B and 3C), despite the comparable amounts of PrP-res in Obihiro-infected ThN and CxN (Fig 1A–1C). In contrast to the enhanced phosphorylation of PERK, protein levels of ATF4 in prion-infected CxN and ThN were not elevated (Fig 3A–3C). We further examined gene expression levels for Atf3, Ddit3, Ppp1r15A, and Hspa5, which encode ATF3, CHOP, GADD34, and Bip, respectively, all of which are known to be up-regulated during ER stress through the PERK-ATF4 axis [23, 24, 4244]. Upregulation of these genes was not observed in prion-infected CxNs and ThNs, except for Hspa5 in prion-infected CxNs at 21dpi (Fig 3D), which can be upregulated by other pathways of UPR, such as ATF6-mediated signaling [45]. As a whole, the results of transcriptional analysis were consistent with no increase ATF4 protein levels. Ratios of p-PERK to total PERK and p-eIF2α to eIF2α were calculated (S3 Fig). Although differences were not statistically significant, p-PERK/total PERK ratios tended to be higher in prion-infected CxN and ThN than mock-infected CxN and ThN. Ratios of p-eIF2α/ total eIF2α did not differ between prion-infected and mock-infected primary neurons. Taken together, the results suggest that phosphorylation of PERK was induced in response to prion propagation in CxNs, which may reflect ER stress in prion-infected CxNs. However, the downstream pathway of PERK was not activated.

Fig 3. ER stress and unfolded protein responses in prion-infected neurons.

Fig 3

(A, B) Immunoblot analysis of molecules involved in the PERK-eIF2α pathway of CxNs (A) and ThNs (B). Protein levels are represented as relative values to the average of mock-infected neurons at each dpi (mean ± SD of 6 replicates from 2 independent experiments; p-PERK, phosphorylated PERK; p-eIF2α, phosphorylated eIF2α; *, p < 0.05 by Student’s t test). (C) Representative blots used for quantification shown in (A) and (B). βIII-tubulin from the same blots were used as internal controls: M, mock-infected neurons; O, Obihiro-infected neurons. For the detection of βIII-tubulin in the analysis of ATF4, peroxidase conjugated anti-rabbit IgG antibodies used for the detection of ATF4 was deactivated with 15% hydrogen peroxide solution, then βIII-tubulin was detected with peroxidase-conjugated anti-chicken IgY second antibody. (D) Expression of genes in the PERK-ATF4 axis analyzed by qRT-PCR. Relative expression levels in Obihiro-infected CxN and ThN to dpi-matched mock-infected neurons are shown as mean ± SD of 3 independent experiments. The broken line indicates relative expression levels = 1 (*, p < 0.05 by One sample t test).

Influence of prion propagation on the amounts of post- and pre-synaptic proteins

Synaptic loss and disfunctions have been observed in the brain of prion-affected animals prior to neuronal loss [4, 46]. Of those alterations, decreases in the protein levels of several synaptic proteins such as SNAP25 and PSD95 have been reported in association with sustained activation of the UPR PERK-eIF2α pathway [30]. To confirm whether prion propagation has any influence on synaptic proteins in cultured neurons, we analyzed a total of 8 post- and pre-synaptic proteins by immunoblotting (Fig 4): post-synaptic AMPAR and NMDAR1 (glutamate receptors), and PSD95 and SAP102 (scaffold proteins); pre-synaptic syntaxin1a, SNAP25, and VAMP2 (SNARE proteins involved in intracellular membrane fusion during exocytosis of neurotransmitters), and synaptophysin (an integral membrane protein of synapse vesicles). At 7 dpi, although most differences were not statistically significant except for SNAP25 (p < 0.05), the levels of these synaptic proteins in Chandler- and Obihiro-infected CxNs showed tendencies toward decreased levels in comparison to mock-infected CxNs (Fig 4A), which allowed us to speculate that prion propagation had a repressive influence on the expression of synaptic proteins in the early phase of prion infection. Intriguingly, this trend unexpectedly reversed; leading to increased synaptic markers by 21 dpi. In particular, the levels of PSD95, syntaxin1a, and VAMP2 in Obihiro-infected CxNs were significantly higher than mock-infected CxNs. Of note, several studies conducted in the last decade using animal models and brain slices also reported that increased numbers of synaptic terminals or spines and the size of post-synaptic densities in the early phases of disease, either just before or after the first detection of PrP-res [30, 47, 48], which were similar to the autonomous neuronal events we observed.

Fig 4. Influence of prion propagation on the levels of post- and pre-synaptic proteins.

Fig 4

(A, B) Immunoblot analysis of post- and pre-synaptic proteins in CxNs (A) and ThNs (B). βIII-tubulin from the same blot was used as internal controls. Protein levels of post-(AMPAR, NMDAR1, PSD95 and SAP102) and pre- (synaptophysin, syntaxin1a, SNAP25 and VAMP2) synapse-associated molecules are represented as relative values to the average of mock-infected neurons at each dpi (mean ± SD of 7–8 biological replicates from 2 independent experiments; *, p < 0.05 by Dunnett’s test using mock-infected neurons as control groups).

Obihiro-infected ThNs at 7 dpi also had a tendency for decreased synaptic protein levels, similar to CxNs. The levels of AMPAR, VAMP2, and SNAP25 were significantly decreased (p < 0.05) compared to mock-infected ThNs (Fig 4B). The decrease in protein levels appeared to be restored by 21 dpi; however, transient increases in synaptic protein levels were less obvious in prion-infected ThNs when compared to CxNs. Taken as a whole, the results show a tendency for the loss of both post- and pre-synaptic proteins in the early stages of prion infection in primary neurons (at 7 dpi). Unexpectedly, the trend was not observed thereafter, despite the continuous prion propagation.

Phosphorylation of PERK in PrPSc-positive neurons

Prion-infected CxNs and ThNs did not show any evident neuronal death or neurodegeneration in the current study. However, considering that the ratio of PrPSc-positive neurons as examined by IFA were 42.9% in CxNs and 54.8% in ThNs including fPrPSc neurons (10.0% and 7.5%, respectively) at 21 dpi, we analyzed individual PrPSc-positive neurons to examine the effects of PrPSc production on neurons more carefully. The mAb 8D5 has the unique property that it selectively binds to native PrPSc in IFA without treating cells with chaotropic agents such as GdnSCN [18, 33], which enabled us to carry out a PrPSc-positive neuron-selective analysis.

We examined neurons in mock- and Obihiro-infected CxNs at 21 dpi for phosphorylated PERK (p-PERK) and PrPSc by immunofluorescence staining to ascertain whether initial UPR events were triggered by PrPSc production (Fig 5). Specificity of anti-phospho-PERK antibody in IFA was confirmed using tunicamycin-treated Neuro2a cells; fluorescent granular signals stained by this antibody appeared more in tunicamycin-treated Neuro2a cells than in untreated Neuro2a cells (S4 Fig). Granular stains of p-PERK were observed in the soma of mock-infected and Obihiro-infected neurons in CxNs at 21dpi, indicating that phosphorylation of PERK is not an event specific to prion infection (Fig 5A). Interestingly, however, intense granular stains of p-PERK were often observed in neurons with a larger number of granular and/or filamentous PrPSc signals (Fig 5A, arrow). Quantitative image analysis of p-PERK and PrPSc signals in each neuron identified a positive correlation between these two molecules in neurons in Obihiro-infected CxN (Fig 5B, correlation coefficient = 0.49). When neurons in Obihiro-infected CxNs were divided into three subpopulations according to the frequency of PrPSc signal at its soma (PrPSc_low, PrPSc+, and PrPSc++), the frequency of p-PERK signals was significantly increased in PrPSc+ neurons, and PrPSc++ neurons when compared to either mock-infected neurons or PrPSc_low neurons (Fig 5C). These data strongly suggest that the production of PrPSc caused ER stress to neurons and accelerated the phosphorylation of PERK, which is known to be the initial event for activating the PERK-ATF4 axis of UPR. The acceleration of PERK phosphorylation was also observed in PrPSc++ neurons of ThN (S5 Fig). We reexamined the expression of ATF4 by co-immunofluorescence staining to see if the PERK-ATF4 axis was activated in those neurons. While induction and nuclear localization of ATF4 were observed in both CxNs treated with tunicamycin, an ER stressor, no ATF4-positive neurons were observed in Obihiro-infected CxNs (Fig 5D).

Synapse densities of PrPSc-positive neurons

In our last series of experiments, we examined synaptic alterations in PrPSc-positive neurons by co-immunostaining. The dense networks of neurites in the primary cultures made it difficult to identify processes from a single neuron by immunofluorescence staining for MAP2; therefore, EGFP was expressed in neurons using an adeno-associated viral vector. In this analysis we focused on the densities at post- and pre-synaptic terminals, i.e., the number of synaptic terminals in a unit volume of a cell, inside and in close proximity to EGFP-expressing neurons by 3D-measurement using a z-series of confocal images (Fig 6A). Obihiro-infected CxNs were divided into three subpopulations according to the density of PrPSc signals as described above (Fig 6B, the right graphs). Quantitative image analyses of post- and pre-synaptic terminals, using PSD95 and synaptophysin as markers respectively, did not show any synaptic losses in Obihiro-infected CxNs at 21 dpi, even in PrPSc++ subpopulations (Fig 6B). The average density of PSD95-positive post-synaptic terminals was slightly higher in PrPSc++ neurons when compared to mock-infected neurons (p = 0.08); which may reflect the increased levels of PSD95 in Obihiro-infected CxN at 21 dpi detected by immunoblot analysis (Fig 4A).

Fig 6. Synapse densities of PrPSc-positive neurons.

Fig 6

Neurons were transduced with the adeno-associated viral vector for EGFP expression before immunostaining of PrPSc and PSD95 or synaptophysin at 21 dpi. Z-stacks of confocal images at a final magnification of 315× were reconstructed in 3D-images for analysis using Imaris software. (A) Representative confocal images (MIP, maximum intensity projection) and reconstructed 3D-images (surfaces) of EGFP-expressing neurons immunostained for PrPSc (with mAB 8D5) and PSD95 in CxNs. (B) Densities of PSD95-positive post-synaptic terminals, synaptophysin-positive pre-synaptic terminals, and PrPSc in CxNs. Densities were defined as the number of signals per unit volume of cell. Obihiro-infected CxNs were analyzed as a whole (Obihiro) and as three subpopulations classified by the density of PrPSc signals in soma and neurites. The rightmost graph shows the density of PrPSc from a representative data set used for pre-synapse quantification. The numbers of neurons used for the measurements were as follows: for post-synaptic density measurements, 20 neurons from mock-infected CxNs and 26 neurons from Obihiro-infected CxNs were used (PrPSc_low, n = 7; PrPSc+, n = 19 including PrPSc++, n = 8). For pre-synaptic density measurements, 73 neurons from mock-infected CxNs and 78 neurons from Obihiro-infected CxNs were used (PrPSc_low, n = 26; PrPSc+, n = 52 including PrPSc++, n = 19). Differences between the groups were analyzed by a Steel’s test using mock-infected neurons as control groups (NS, no significant differences; ***, p < 0.001).

Discussion

Conversion of neuronal PrPC into PrPSc is a central event that leads to neurodegenerative consequences in prion diseases [79]; however, the precise process of neurodegeneration and its molecular mechanisms remain unclear. Although the involvement of microglia in the neuropathogenesis of prion diseases is evident [4951], little is known about autonomous neuronal responses to prion propagation, which may cause neuronal death. Hannaoui et al. reported that primary neuronal cultures from mouse cerebellum and cortex showed neuronal losses after prion exposure [17], suggesting that primary neuronal cultures are a versatile ex vivo model for analyzing the molecular mechanisms of neurodegeneration by prion infection. However, it is difficult to evaluate autonomous neuronal response to prion propagation due to the presence of astrocytes in those cultures, particularly if cultures are kept for long periods [17]. Thus, in the current study, we used neuron-enriched primary cultures from cortices and thalami by inhibiting astrocyte growth with AraC treatment, which inhibits astrocyte growth [18].

Previously, Cronier et al. observed an increase of apoptotic cells with fragmented nuclei in prion-infected CGNs cultured on an astrocyte feeder layer [16]. Hannaoui et al. reported decreases in the proportion of MAP2-positive neurons in prion-exposed CGNs from 14–21 days post exposure (dpe), as well as in striatal and cortical neuronal cultures from 7–11 dpe; GFAP-positive astrocytes accounted for 20–30% of cells when neuronal losses were observed [17]. In contrast to these studies, no continuous decline of NeuN-positive neurons or MAP-2-positive neurite densities in prion-infected cells were observed in CxNs or ThNs infected with either the Chandler or Obihiro prion strains (Fig 2A), in spite of the continuous increasing of PrP-res levels over 28 dpi. Differences in experimental conditions, including mouse strains used for neuronal cultures and prion strains, may account for some of the inconsistency of observed neurotoxicity. One of critical differences between Hannaoui’s study and the current study was presence of astrocytes. Astrocytes can be infected with prions and support the propagation and transmission of prions in cell cultures [16, 5254] and change the microenvironment, which accelerates degeneration of prion-infected neurons [55]. Thus, it is possible that efficient prion propagation in primary neuronal cultures with astrocytes attributes to the differences in observed neurotoxicity.

Induction of ER stress, which is recognized by upregulation of ER chaperon proteins, has been reported in the brains of patients with sporadic or variant CJD [28, 29] and prion-infected mice [28]. The involvement of UPR, in particular the PERK-eIF2α-ATF4 pathway, in the pathogenesis of prion diseases has been demonstrated by the inhibition of the PERK activity and/or the reduction of eIF2α phosphorylation levels which successfully prolonged the survival of prion-infected transgenic mice overexpressing PrP [30, 31]. Thus, we analyzed molecules involved in the PERK-eIF2α-ATF4 pathway of UPR to assess whether UPR was evoked in prion-infected CxNs and ThNs as an autonomous neuronal response. Although no clear tendency of activation of this pathway was observed when cultures were analyzed as a whole (Fig 3), a finer analysis of individual neurons by IFA identified a positive correlation between the amounts of PrPSc and p-PERK in cortical neurons at 21 dpi, indicating that the production of PrPSc directly provoked neuronal ER stress and enhanced the phosphorylation of PERK as an autonomous neuronal response (Fig 5A–5C). ATF4 is a pivotal transcription factor for full activation of the PERK-eIF2α pathway ultimately transducing ER stress into a CHOP-mediated proapoptotic phase [27]. Indeed, time-dependent increases of CHOP levels and increased translation of ATF4 in the brain of prion-infected transgenic mice suggests the activation of this axis with the disease progression [30]. Interestingly, neither induction of ATF4 nor upregulation of its downstream genes was observed, even in PrPSc++ neurons in prion-infected CxN (Fig 5C). Our data suggests that ER stress and PERK phosphorylation are enhanced by prion propagation as an autonomous neuronal response, whereas activation of downstream cascades in the PERK-eIF2α-ATF4 pathway will not take place as a consequence of autonomous neuronal response to prion propagation.

Given that prion diseases have a long preclinical phase of prion propagation before exhibiting clinical manifestations in vivo [56], we cannot exclude the possibility that level or duration of PrPSc accumulation in our prion-infected neurons is enough to trigger ER stress but not sufficient to activate UPR that leads to neurodegeneration. It is probable that activated microglia and/or astrocytes play intrinsic roles in the process of neurodegeneration in prion diseases [57, 58]. Depletion and inhibition of microglial activity alters the disease progression of prion-infected mice [49, 50, 59]. Astrogliosis may also modify the neuropathological processes of prion diseases [60, 61]. Recently, Smith et al. reported that changes in astrocyte secretome by UPR-response in astrocytes as the cause of non-neuron autonomous neurodegeneration in prion diseases, although changes in astrocytes by prion-induced UPR, which may directly cause the neurodegeneration, are not fully understood [62]. There are several pieces of evidence for so-called “cross talk” [63, 64] between neurons and glial cells that regulates their activation states; transducing both neuroprotective and neurotoxic signals under pathological conditions. Therefore, additional stimuli, possibly from activated microglia or astrocytes, may be required for the full activation of the PERK-eIF2α-ATF4 pathway in the brains of prion-infected mice to produce the neurodegeneration observed in prion diseases.

Decrease in levels of synaptic proteins has been observed in brains of prion-infected mice [4, 46, 65]. It is known that phosphorylation of eIF2α by p-PERK induces the global repression of translation as a consequence of UPR [21], which targets include several synaptic proteins [30]. Thus, we examined the expression of post- and pre-synaptic proteins in individual neurons at 21 dpi; however, no differences were observed in the densities of PSD95- or synaptophysin-positive granular signals between mock-infected and prion-infected neurons even in PrPSc++ neurons (Fig 6). These results suggest that not only selective translation of ATF4, but also repression of global protein synthesis was not autonomously induced in prion-infected neurons by PERK phosphorylation, consistent with no differences in p-eIF2α levels being observed between mock- and prion-infected neurons at 21 dpi (Fig 3). Incidentally, at 7 dpi, we found that eIF2α phosphorylation levels were significantly higher, which coincided with the decreased expression of several synaptic proteins in prion-infected CxNs versus mock-infected CxNs in immunoblot analyses. This suggests that activation of UPR via p-PERK is somehow limited to a relatively early phase after exposure to prions, even though the ER stress and phosphorylation of PERK are sustained in prion-infected neurons. The importance of early PERK-eIF2α pathway activation in neurodegenerative disorders has been also indicated by p-PERK in pre-tangle neurons rather than neurons with neurofibrillary tangles in AD [66], and in dopaminergic neurons with diffused α-synuclein in PD postmortem brains [67]. Although we focused on the later time point (21 dpi), when PrPSc accumulation was observed in neurons, it is of interest if acute toxicity of PrPSc [15, 41] or an immediate response of neurons to prions stimulates the activation of PERK and its downstream pathways despite significantly lower level of PrPSc accumulation than later time periods. Alternatively, it is reported that PrPSc causes acute toxicity in excitatory synapses through glutamate receptor and p38 MAPK activation, which is not presumably related to UPR [68]. Thus, analyses of earlier time points are also required to evaluate neuron-autonomous responses to prion infection.

We described the induction of ER stress as genuine neuronal responses to prion propagation; however, it did not proceed to a pro-apoptotic phase or synaptic losses autonomously in neurons ex vivo. Our findings suggest the presence of non-neuronal factor(s) in the mechanism of neurodegeneration in prion diseases, which may provide clues for therapeutics to prion diseases and other misfolding disorders.

Supporting information

S1 Fig. Percentages of NeuN-positive neurons and GFAP-positive astrocytes in primary cultures used in this study.

Primary neuronal cultures were treated with antimitotic AraC at 0.25 μM from 4 days in vitro (div) to 7 div in the first week. Cells were immunostained for NeuN and GFAP to identify neurons and astrocytes in the cultures at 21 dpi (corresponds to 28 div). MetaMorph software was used to set a threshold of fluorescent intensity of each cell marker. Cells which were not immunostained for NeuN and GFAP, and have shrunk and condensed nuclei (DAPI-positive area ≤ 80 μm2) were considered as putative dead cells and removed from counting. Images show representative CxNs and ThNs cultured under each condition. Arrows, filled arrowheads, and open arrowheads indicate NeuN-positive neurons, GFAP-positive astrocytes, and unidentified cells (NeuN- and GFAP-negative cells), respectively. The table shows percentages of each cell type in the cultures. Bar, 50 μm.

(TIF)

S2 Fig. Representative immunofluorescence images.

Representative immunofluorescence images of (A) CxNs and (B) ThNs used for image analyses shown in Fig 2. From the left, panels show merged images, subsets of NeuN and DAPI, and binary images of MAP2 staining. (C & D) Unnormalized values of neuronal cell density and neurite density for (C) CxNs and (D) ThNs measured by MetaMorph software. Cell density and neurite density were defined as the number of NeuN-positive nuclei per 0.01 mm2 and the surface coverage (%) by MAP2-positive neurites, respectively. Bar graphs show mean ± SD of 9 replicates from 3 independent experiments. Bars = 50 μm.

(TIF)

S3 Fig. Ratios of phosphorylated PERK (p-PERK) to total PERK (t-PERK) and phosphorylated eIF2α (p-eIF2α) to total eIF2α (t-eIF2α).

Phosphorylation levels of PERK and eIF2α were assessed as ratio between the phosphorylated and total protein signals quantified by immunoblotting described in Fig 3. Ratios of p-PERK/t-PERK (top) and p-eIF2α/ t-eIF2α (bottom) are indicated in Tables (mean ± SD). Although differences were not statistically significant, p-PERK/t-PERK ratios tended to be higher in prion-infected CxNs and ThNs than mock-infected CxNs and ThNs. In contrast to ratios of p-PERK/t-PERK, those of p-eIF2α/t-eIF2α did not differ between prion-infected and mock-infected primary neurons.

(TIF)

S4 Fig. Immunostaining for p-PERK (Thr980) using a rabbit monoclonal antibody (16F8) in tunicamycin-treated Neuro2a cells.

Immunofluorescence staining for p-PERK (green) with counter staining for nuclei (DAPI, blue) was carried out using Neuro2a cell treated with tunicamycin at indicated concentrations for 12 hrs. Images are shown as maximum intensity projection created from z-series stacks of confocal images. Fluorescent granular signals stained by this antibody appeared more in tunicamycin-treated Neuro2a cells (5.0 μg/ml) than in untreated Neuro2a cells, indicating that the specificity of reaction of this antibody in IFA. Bars, 10 μm.

(TIF)

S5 Fig. Phosphorylation of PERK in PrPSc-positive thalamic neurons.

(A) Multiple immunofluorescence staining for p-PERK and PrPSc with counter staining for MAP2 and nuclei (DAPI) in ThNs at 21 dpi. PrPSc was stained with mAb 8D5. Figures are shown as maximum intensity projection images. Arrows indicate a PrPSc++ neuron. Bars, 50 μm. (B, C) Quantification of p-PERK and PrPSc in individual neurons by 3D-image analysis using Imaris software. Each dot in the scatter diagram (B) represents an individual thalamic neuron although some neurons were spotted at the same position (r, correlation coefficient). In (C), Obihiro-infected ThN was analyzed as a whole (Obihiro) and as three subpopulations classified by the frequency of PrPSc signals at the soma. The definition of the three subpopulations and the number of cells used for this analysis are as follows: PrPSc_low (< 4 PrPSc signals/cell, n = 49), PrPSc+ (≥ 4 PrPSc signals/cell, n = 26, including PrPSc++), and PrPSc++ (≥ 13 PrPSc signals/cell, n = 12). The number of cells in mock-infected ThN and Obihiro-infected ThN used for the analysis are n = 49 and n = 75, respectively. Differences between the groups were analyzed by Steel-Dwass’s multiple comparison tests. *, p < 0.05

(TIF)

S1 Raw images

(PDF)

Acknowledgments

We thank Dr. Roth B. for pAAV-hSyn-EGFP, and to Dr. Gradinaru V. for pUCmini-iCAP-PHP.eB. We also thank Zensho Co., Ltd, for the BSL3 facility.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by Grant-in-aid for JSPS Research Fellow Grant Number JP18J12535 (M.T.). This work was also supported by a Grant-in-Aid for Science Research (A) (JSPS KAKENHI Grant Number JP 15H02475) (M.H.) and a grant from the Program for Leading Graduate Schools (F01) (M.H.) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. This work was also supported by grants for TSE research (H29-Shokuhin-Ippan-004) (M.H.) from the Ministry of Health, Labour and Welfare of Japan.

References

  • 1.Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol. 2011;3(1):a006833 Epub 2011/03/23. 10.1101/cshperspect.a006833 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Prusiner SB. Prions. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(23):13363–83. Epub 1998/11/13. 10.1073/pnas.95.23.13363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chiti Z, Knutsen OM, Betmouni S, Greene JR. An integrated, temporal study of the behavioural, electrophysiological and neuropathological consequences of murine prion disease. Neurobiol Dis. 2006;22(2):363–73. Epub 2006/01/25. 10.1016/j.nbd.2005.12.002 . [DOI] [PubMed] [Google Scholar]
  • 4.Cunningham C, Deacon R, Wells H, Boche D, Waters S, Diniz CP, et al. Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur J Neurosci. 2003;17(10):2147–55. Epub 2003/06/06. 10.1046/j.1460-9568.2003.02662.x . [DOI] [PubMed] [Google Scholar]
  • 5.Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73(7):1339–47. Epub 1993/07/02. 10.1016/0092-8674(93)90360-3 . [DOI] [PubMed] [Google Scholar]
  • 6.Manson JC, Clarke AR, McBride PA, McConnell I, Hope J. PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration. 1994;3(4):331–40. Epub 1994/12/01. . [PubMed] [Google Scholar]
  • 7.Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 1996;379(6563):339–43. Epub 1996/01/25. 10.1038/379339a0 . [DOI] [PubMed] [Google Scholar]
  • 8.Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, Powell AD, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron. 2007;53(3):325–35. Epub 2007/02/03. 10.1016/j.neuron.2007.01.005 . [DOI] [PubMed] [Google Scholar]
  • 9.Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 2003;302(5646):871–4. Epub 2003/11/01. 10.1126/science.1090187 . [DOI] [PubMed] [Google Scholar]
  • 10.Butler DA, Scott MR, Bockman JM, Borchelt DR, Taraboulos A, Hsiao KK, et al. Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J Virol. 1988;62(5):1558–64. Epub 1988/05/01. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Race RE, Caughey B, Graham K, Ernst D, Chesebro B. Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol. 1988;62(8):2845–9. Epub 1988/08/01. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Schatzl HM, Laszlo L, Holtzman DM, Tatzelt J, DeArmond SJ, Weiner RI, et al. A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J Virol. 1997;71(11):8821–31. Epub 1997/10/29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ciccotosto GD, Jana M, Cappai R. Neurotoxicity of Prion Peptides on Cultured Cerebellar Neurons. Methods Mol Biol. 2017;1658:147–65. Epub 2017/09/02. 10.1007/978-1-4939-7244-9_12 . [DOI] [PubMed] [Google Scholar]
  • 14.Alleaume-Butaux A, Nicot S, Pietri M, Baudry A, Dakowski C, Tixador P, et al. Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation. PLoS Pathog. 2015;11(8):e1005073 Epub 2015/08/05. 10.1371/journal.ppat.1005073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Fang C, Imberdis T, Garza MC, Wille H, Harris DA. A Neuronal Culture System to Detect Prion Synaptotoxicity. PLoS Pathog. 2016;12(5):e1005623 Epub 2016/05/27. 10.1371/journal.ppat.1005623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Cronier S, Laude H, Peyrin JM. Prions can infect primary cultured neurons and astrocytes and promote neuronal cell death. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(33):12271–6. Epub 2004/08/11. 10.1073/pnas.0402725101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hannaoui S, Maatouk L, Privat N, Levavasseur E, Faucheux BA, Haik S. Prion propagation and toxicity occur in vitro with two-phase kinetics specific to strain and neuronal type. J Virol. 2013;87(5):2535–48. Epub 2012/12/21. 10.1128/jvi.03082-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Tanaka M, Fujiwara A, Suzuki A, Yamasaki T, Hasebe R, Masujin K, et al. Comparison of abnormal isoform of prion protein in prion-infected cell lines and primary-cultured neurons by PrPSc-specific immunostaining. J Gen Virol. 2016;97(8):2030–42. Epub 2016/06/09. 10.1099/jgv.0.000514 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519–29. Epub 2007/06/15. 10.1038/nrm2199 . [DOI] [PubMed] [Google Scholar]
  • 20.Roussel BD, Kruppa AJ, Miranda E, Crowther DC, Lomas DA, Marciniak SJ. Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol. 2013;12(1):105–18. Epub 2012/12/15. 10.1016/s1474-4422(12)70238-7 . [DOI] [PubMed] [Google Scholar]
  • 21.Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature. 1999;397(6716):271–4. Epub 1999/02/04. 10.1038/16729 . [DOI] [PubMed] [Google Scholar]
  • 22.Kimball SR. Eukaryotic initiation factor eIF2. Int J Biochem Cell Biol. 1999;31(1):25–9. Epub 1999/04/27. 10.1016/s1357-2725(98)00128-9 . [DOI] [PubMed] [Google Scholar]
  • 23.Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, et al. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol. 2004;24(3):1365–77. Epub 2004/01/20. 10.1128/mcb.24.3.1365-1377.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ma Y, Hendershot LM. Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem. 2003;278(37):34864–73. Epub 2003/07/04. 10.1074/jbc.M301107200 . [DOI] [PubMed] [Google Scholar]
  • 25.Galehdar Z, Swan P, Fuerth B, Callaghan SM, Park DS, Cregan SP. Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010;30(50):16938–48. Epub 2010/12/17. 10.1523/jneurosci.1598-10.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol. 2001;21(4):1249–59. Epub 2001/02/07. 10.1128/mcb.21.4.1249-1259.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998;12(7):982–95. Epub 1998/05/09. 10.1101/gad.12.7.982 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hetz C, Russelakis-Carneiro M, Maundrell K, Castilla J, Soto C. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. Embo j. 2003;22(20):5435–45. Epub 2003/10/09. 10.1093/emboj/cdg537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Yoo BC, Krapfenbauer K, Cairns N, Belay G, Bajo M, Lubec G. Overexpressed protein disulfide isomerase in brains of patients with sporadic Creutzfeldt-Jakob disease. Neurosci Lett. 2002;334(3):196–200. Epub 2002/11/28. 10.1016/s0304-3940(02)01071-6 . [DOI] [PubMed] [Google Scholar]
  • 30.Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, et al. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature. 2012;485(7399):507–11. Epub 2012/05/25. 10.1038/nature11058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med. 2013;5(206):206ra138 10.1126/scitranslmed.3006767 Epub 2013/10/11. . [DOI] [PubMed] [Google Scholar]
  • 32.Kim CL, Umetani A, Matsui T, Ishiguro N, Shinagawa M, Horiuchi M. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology. 2004;320(1):40–51. Epub 2004/03/09. 10.1016/j.virol.2003.10.026 . [DOI] [PubMed] [Google Scholar]
  • 33.Masujin K, Kaku-Ushiki Y, Miwa R, Okada H, Shimizu Y, Kasai K, et al. The N-terminal sequence of prion protein consists an epitope specific to the abnormal isoform of prion protein (PrP(Sc)). PLoS One. 2013;8(2):e58013 Epub 2013/03/08. 10.1371/journal.pone.0058013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Uryu M, Karino A, Kamihara Y, Horiuchi M. Characterization of prion susceptibility in Neuro2a mouse neuroblastoma cell subclones. Microbiology and immunology. 2007;51(7):661–9. Epub 2007/07/21. 10.1111/j.1348-0421.2007.tb03954.x . [DOI] [PubMed] [Google Scholar]
  • 35.Nakamitsu S, Kurokawa A, Yamasaki T, Uryu M, Hasebe R, Horiuchi M. Cell density-dependent increase in the level of protease-resistant prion protein in prion-infected Neuro2a mouse neuroblastoma cells. J Gen Virol. 2010;91(Pt 2):563–9. Epub 2009/10/09. 10.1099/vir.0.016287-0 . [DOI] [PubMed] [Google Scholar]
  • 36.Yamasaki T, Suzuki A, Hasebe R, Horiuchi M. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells. PLoS One. 2014;9(9):e106516 Epub 2014/09/03. 10.1371/journal.pone.0106516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Yamasaki T, Suzuki A, Shimizu T, Watarai M, Hasebe R, Horiuchi M. Characterization of intracellular localization of PrP(Sc) in prion-infected cells using a mAb that recognizes the region consisting of aa 119–127 of mouse PrP. J Gen Virol. 2012;93(Pt 3):668–80. Epub 2011/11/18. 10.1099/vir.0.037101-0 . [DOI] [PubMed] [Google Scholar]
  • 38.Challis RC, Ravindra Kumar S, Chan KY, Challis C, Beadle K, Jang MJ, et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc. 2019;14(2):379–414. Epub 2019/01/11. 10.1038/s41596-018-0097-3 . [DOI] [PubMed] [Google Scholar]
  • 39.Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20(8):1172–9. Epub 2017/07/04. 10.1038/nn.4593 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Shindoh R, Kim CL, Song CH, Hasebe R, Horiuchi M. The region approximately between amino acids 81 and 137 of proteinase K-resistant PrPSc is critical for the infectivity of the Chandler prion strain. J Virol. 2009;83(8):3852–60. Epub 2009/01/30. 10.1128/jvi.01740-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Foliaki ST, Lewis V, Finkelstein DI, Lawson V, Coleman HA, Senesi M, et al. Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species. PLoS Pathog. 2018;14(8):e1007214 Epub 2018/08/09. 10.1371/journal.ppat.1007214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ma Y, Brewer JW, Diehl JA, Hendershot LM. Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J Mol Biol. 2002;318(5):1351–65. Epub 2002/06/27. 10.1016/s0022-2836(02)00234-6 . [DOI] [PubMed] [Google Scholar]
  • 43.Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6(5):1099–108. Epub 2000/12/07. 10.1016/s1097-2765(00)00108-8 . [DOI] [PubMed] [Google Scholar]
  • 44.Luo S, Baumeister P, Yang S, Abcouwer SF, Lee AS. Induction of Grp78/BiP by translational block: activation of the Grp78 promoter by ATF4 through and upstream ATF/CRE site independent of the endoplasmic reticulum stress elements. J Biol Chem. 2003;278(39):37375–85. Epub 2003/07/23. 10.1074/jbc.M303619200 . [DOI] [PubMed] [Google Scholar]
  • 45.Yoshida H, Haze K, Yanagi H, Yura T, Mori K. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J Biol Chem. 1998;273(50):33741–9. Epub 1998/12/05. 10.1074/jbc.273.50.33741 . [DOI] [PubMed] [Google Scholar]
  • 46.Mallucci GR. Prion neurodegeneration: starts and stops at the synapse. Prion. 2009;3(4):195–201. Epub 2009/11/06. 10.4161/pri.3.4.9981 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Siskova Z, Page A, O'Connor V, Perry VH. Degenerating synaptic boutons in prion disease: microglia activation without synaptic stripping. Am J Pathol. 2009;175(4):1610–21. Epub 2009/09/26. 10.2353/ajpath.2009.090372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Campeau JL, Wu G, Bell JR, Rasmussen J, Sim VL. Early increase and late decrease of purkinje cell dendritic spine density in prion-infected organotypic mouse cerebellar cultures. PLoS One. 2013;8(12):e81776 Epub 2013/12/07. 10.1371/journal.pone.0081776 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Carroll JA, Race B, Williams K, Striebel J, Chesebro B. Microglia Are Critical in Host Defense against Prion Disease. J Virol. 2018;92(15). Epub 2018/05/18. 10.1128/jvi.00549-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Gomez-Nicola D, Fransen NL, Suzzi S, Perry VH. Regulation of microglial proliferation during chronic neurodegeneration. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2013;33(6):2481–93. Epub 2013/02/09. 10.1523/jneurosci.4440-12.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zhu C, Herrmann US, Falsig J, Abakumova I, Nuvolone M, Schwarz P, et al. A neuroprotective role for microglia in prion diseases. J Exp Med. 2016;213(6):1047–59. Epub 2016/05/18. 10.1084/jem.20151000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Hollister JR, Lee KS, Dorward DW, Baron GS. Efficient uptake and dissemination of scrapie prion protein by astrocytes and fibroblasts from adult hamster brain. PLoS One. 2015;10(1):e0115351 Epub 2015/01/31. 10.1371/journal.pone.0115351 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Krejciova Z, Alibhai J, Zhao C, Krencik R, Rzechorzek NM, Ullian EM, et al. Human stem cell-derived astrocytes replicate human prions in a PRNP genotype-dependent manner. J Exp Med. 2017;214(12):3481–95. Epub 2017/11/17. 10.1084/jem.20161547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Victoria GS, Arkhipenko A, Zhu S, Syan S, Zurzolo C. Astrocyte-to-neuron intercellular prion transfer is mediated by cell-cell contact. Sci Rep. 2016;6:20762 Epub 2016/02/10. 10.1038/srep20762 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Cronier S, Carimalo J, Schaeffer B, Jaumain E, Beringue V, Miquel MC, et al. Endogenous prion protein conversion is required for prion-induced neuritic alterations and neuronal death. Faseb j. 2012;26(9):3854–61. Epub 2012/06/05. 10.1096/fj.11-201772 . [DOI] [PubMed] [Google Scholar]
  • 56.Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature. 2011;470(7335):540–2. Epub 2011/02/26. 10.1038/nature09768 . [DOI] [PubMed] [Google Scholar]
  • 57.Maragakis NJ, Rothstein JD. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol. 2006;2(12):679–89. Epub 2006/11/23. 10.1038/ncpneuro0355 . [DOI] [PubMed] [Google Scholar]
  • 58.Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57–69. Epub 2006/12/21. 10.1038/nrn2038 . [DOI] [PubMed] [Google Scholar]
  • 59.Nakagaki T, Satoh K, Ishibashi D, Fuse T, Sano K, Kamatari YO, et al. FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice. Autophagy. 2013;9(9):1386–94. Epub 2013/06/27. 10.4161/auto.25381 . [DOI] [PubMed] [Google Scholar]
  • 60.Schultz J, Schwarz A, Neidhold S, Burwinkel M, Riemer C, Simon D, et al. Role of interleukin-1 in prion disease-associated astrocyte activation. Am J Pathol. 2004;165(2):671–8. Epub 2004/07/28. 10.1016/s0002-9440(10)63331-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Hartmann K, Sepulveda-Falla D, Rose IVL, Madore C, Muth C, Matschke J, et al. Complement 3(+)-astrocytes are highly abundant in prion diseases, but their abolishment led to an accelerated disease course and early dysregulation of microglia. Acta Neuropathol Commun. 2019;7(1):83 Epub 2019/05/24. 10.1186/s40478-019-0735-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Smith HL, Freeman OJ, Butcher AJ, Holmqvist S, Humoud I, Schatzl T, et al. Astrocyte Unfolded Protein Response Induces a Specific Reactivity State that Causes Non-Cell-Autonomous Neuronal Degeneration. Neuron. 2020;105(5):855–66.e5. Epub 2020/01/12. 10.1016/j.neuron.2019.12.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Neuroscience. 2009;158(3):1122–32. Epub 2008/10/14. 10.1016/j.neuroscience.2008.09.009 . [DOI] [PubMed] [Google Scholar]
  • 64.Garden GA, La Spada AR. Intercellular (mis)communication in neurodegenerative disease. Neuron. 2012;73(5):886–901. Epub 2012/03/13. 10.1016/j.neuron.2012.02.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Hilton KJ, Cunningham C, Reynolds RA, Perry VH. Early Hippocampal Synaptic Loss Precedes Neuronal Loss and Associates with Early Behavioural Deficits in Three Distinct Strains of Prion Disease. PLoS One. 2013;8(6):e68062 Epub 2013/07/11. 10.1371/journal.pone.0068062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol. 2009;174(4):1241–51. Epub 2009/03/07. 10.2353/ajpath.2009.080814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun. 2007;354(3):707–11. Epub 2007/01/27. 10.1016/j.bbrc.2007.01.043 . [DOI] [PubMed] [Google Scholar]
  • 68.Fang C, Wu B, Le NTT, Imberdis T, Mercer RCC, Harris DA. Prions activate a p38 MAPK synaptotoxic signaling pathway. PLoS Pathog. 2018;14(9):e1007283 Epub 2018/09/21. 10.1371/journal.ppat.1007283 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Roberto Chiesa

18 Mar 2020

PONE-D-20-03488

Enhanced phosphorylation of PERK in primary cultured neurons as an autonomous neuronal response to prion infection

PLOS ONE

Dear Dr. Horiuchi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

It is important that all the technical points are addressed, and your results are discussed in light of previous studies investigating the role of the UPR in prion pathogenesis.

We would appreciate receiving your revised manuscript by May 02 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Roberto Chiesa

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this manuscript, Tanaka and colleagues analysed the autonomous neuronal response to prion infection. They used neuron-enriched primary cultures of cortical, which have been previously characterised (Tanaka M. et al., 2016), and thalamic neurons. They infected neurons with the mouse-adapted scrapie Chandler and Obihiro strains.

They found that both cortical and thalamic cultures successfully propagate prions Chandler and Obihiro strains. Despite the continuous increasing of PrPSc levels in neurons over time, no obvious and progressive neuronal loss or neurite alteration were observed in prion-infected neurons compared to mock-infected neurons. The authors measured neuron density as NeuN positive nuclei per 0.01 mm2. I wonder what the percentage of NeuN positive cells on the total DAPI positive cells is, since it seems that only few cells are positive to NeuN in fig S1.

Phosphorylation of PERK was enhanced in prion-infected cortical neurons as shown by immunoblot analysis. As normally phosphorylation level of PERK and eIF2alpha is expressed as ratio between the phosphorylated and total protein signal, I suggest to express the data in figure 3 as ratio p-PERK/PERK and p-eIF2α/eIF2α. The authors performed also a finer IF analysis of individual p-PERK in PrPSc-positive cortical neurons at 21 dpi, that demonstrated a positive correlation between the number of PrPSc and p-PERK granular stains.

Interestingly, despite PrPSc production caused PERK phosphorylation, neither translational repression of synaptic protein synthesis nor activation of downstream effectors of PERK-eIf2α pathway were observed. These results indicate that PrPSc production induces ER stress in cortical neurons in cell autonomous manner, but this is not sufficient to fully activate the UPR leading to neurodegeneration. The authors suggest the involvement of neuronal non autonomous factors in the mechanisms of neurodegeneration in prion disease. This is in agreement with the recent finding that dysregulation of PERK signaling in astrocytes induces a specific reactivity state causing non-cell autonomous pathogenic mechanism in prion neurodegeneration (Smith H.L. et al., 2020).

All experiments are well done and have the appropriate controls.

This work is well written and clear.

Typing errors:

line 28 alternations (alterations)

line 109 autonomaous neurnal (autonomous neuronal)

In line 283 is SE or SD?

The percentage of PrPSc positive ThN is 54.8% (line 274) or 52.8% (line 422)?

line 503 *p<0.001 (***p<0.001)

Reviewer #2: In this paper, the authors investigate the role of the UPR in prion infection using cultured cortical and thalamic neurons in combination with Western blotting and immunostaining. They conclude that, although prion infection is correlated with increased PERK phosphorylation, there was no evidence of subsequent translational repression of synaptic protein synthesis or activation of downstream steps of the UPR pathway. There has been previous work on the role of the UPR in prion infection, most notably by Mallucci and colleagues, who showed that prion infection in vivo fully activates the PERK branch of the UPR, and that genetic or pharmacological manipulation this branch mitigates prion disease symptoms and pathology in mice. In contract, Fang et al. (PLoS Pathogens 14(9): e1007283, 2018) showed that UPR inhibitors had no effect on the acute synaptotoxic effects of PrPSc on cultured hippocampal neurons.

This paper aims to investigate an important question: the molecular and cellular mechanisms by which prions damage neurons. However, there are both conceptual as well as technical flaws, which detract from the impact of the paper. As a result, this study does not make a major contribution to advancing knowledge about the role of the UPR in prion diseases.

Major criticisms:

1. Why does prion infection activate only PERK phosphorylation, but not the downstream steps of the pathway? The authors do not offer much speculation or experimental evidence on this issue.

2. Why does PERK phosphorylation increase only in cortical and not thalamic neurons? This calls into question the generality of the results.

3. The authors do not do a very good job reconciling their results with those of Mallucci or Fang et al. (2018).

Technical criticisms:

4. What is the proportion of neurons in culture? When was AraC added to the cultures? These primary cultures probably contain a mixture of cell types, and non-neuronal cells may account for up to 30% of total cells (Ref. #17). Therefore, immunoblot analysis for protein levels (Fig. 3) will represent the responses of multiple cell types, and not just neurons. Even though the authors normalized their Western blot data using βIII tubulin, this will only equalize the proportion of neuronally-derived protein in each sample, but not remove the effect of non-neuronal cells. This problem is compounded in the normalization for the pre- and post-synaptic markers (Fig. 4), since the proportion of neuronal vs. non-neuronal cells is likely changing over time even in the absence of prion infection.

5. The authors used only the phospho-PERK (Thr980) (16F8) antibody, but this product is recommend only for Western blots. This raises a question about the specificity of the IF staining using this antibody.

Reviewer #3: The manuscript by M. Tanaka and colleagues describes enhanced phosphorylation of PERK in primary neuronal cultures as a response to prion infection. The authors performed a very careful and well controlled analysis and studied the molecular mechanisms of neurodegeneration in prion disease in primary cells. The authors infected neuron-enriched primary cultures (cortical and thalamic) with two strains of prions and tested them for alterations in neuronal and neurite integrity in immunoblot, RT-PCR and immunofluorescence assays. Only minor indications for ER stress were found, like increased phosphorylation of PERK, and there was no translation into full activation of an unfolded protein response (UPR) in these infected primary neurons. The major conclusion from these findings was that non-neuronal factors are needed for full execution of UPR in prion-infected neurons, most likely coming from astrocytes. Evidence for this conclusion is very compelling, although the authors did not discuss in the manuscript how pure their neuronal cultures at the end really are. They provide references to earlier publications, but it is necessary to provide this data or at least discuss them. Taken together, the authors provide important data which are novel, significant and which have the potential to exert an impact to the field. The manuscript is well done, experiments are clearly described and well controlled, and conclusions are fully justified by the experimental data.

Minor points:

1) Page 8/Immunoblotting: Duration of PK digestion should be indicated.

2) Page 8/IF and page 18: mAb 8D5 should also be described in Materials and Methods, with clearly mentioning that no GndSCN step is done.

3) Fig. 1A/B: It would help to indicate in the figure and/or charts that A shows CxN and B ThN neurons.

4) Fig 1: The rationale of relating quantification of PrPSc to day 7 p.i. should be provided.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Roberto Chiesa

20 May 2020

Enhanced phosphorylation of PERK in primary cultured neurons as an autonomous neuronal response to prion infection

PONE-D-20-03488R1

Dear Dr. Horiuchi,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Roberto Chiesa

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Please amend the following in the final version of the manuscript:

1) Page 16, line 369-371: "In contrast to ratios of p-PERK/total PERK, those of p-eIF2α/ total eIF2α did not differ between prion-infected and mock-infected primary neurons. "

"In contrast to ratios of p-PERK/total PERK..." should be removed since in the previous sentence it is stated that there is no statistically significant differences in p-PERK/total PERK ratios.

2) Page 25, line 591: "...no differences were observed in the densities PSD95-..." should read "...no differences were observed in the densities of PSD95-..."

3) page 26, line 14: please replace "highlight" with "suggest".

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: Yes: Hermann M. Schatzl

Acceptance letter

Roberto Chiesa

22 May 2020

PONE-D-20-03488R1

Enhanced phosphorylation of PERK in primary cultured neurons as an autonomous neuronal response to prion infection

Dear Dr. Horiuchi:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Roberto Chiesa

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Percentages of NeuN-positive neurons and GFAP-positive astrocytes in primary cultures used in this study.

    Primary neuronal cultures were treated with antimitotic AraC at 0.25 μM from 4 days in vitro (div) to 7 div in the first week. Cells were immunostained for NeuN and GFAP to identify neurons and astrocytes in the cultures at 21 dpi (corresponds to 28 div). MetaMorph software was used to set a threshold of fluorescent intensity of each cell marker. Cells which were not immunostained for NeuN and GFAP, and have shrunk and condensed nuclei (DAPI-positive area ≤ 80 μm2) were considered as putative dead cells and removed from counting. Images show representative CxNs and ThNs cultured under each condition. Arrows, filled arrowheads, and open arrowheads indicate NeuN-positive neurons, GFAP-positive astrocytes, and unidentified cells (NeuN- and GFAP-negative cells), respectively. The table shows percentages of each cell type in the cultures. Bar, 50 μm.

    (TIF)

    S2 Fig. Representative immunofluorescence images.

    Representative immunofluorescence images of (A) CxNs and (B) ThNs used for image analyses shown in Fig 2. From the left, panels show merged images, subsets of NeuN and DAPI, and binary images of MAP2 staining. (C & D) Unnormalized values of neuronal cell density and neurite density for (C) CxNs and (D) ThNs measured by MetaMorph software. Cell density and neurite density were defined as the number of NeuN-positive nuclei per 0.01 mm2 and the surface coverage (%) by MAP2-positive neurites, respectively. Bar graphs show mean ± SD of 9 replicates from 3 independent experiments. Bars = 50 μm.

    (TIF)

    S3 Fig. Ratios of phosphorylated PERK (p-PERK) to total PERK (t-PERK) and phosphorylated eIF2α (p-eIF2α) to total eIF2α (t-eIF2α).

    Phosphorylation levels of PERK and eIF2α were assessed as ratio between the phosphorylated and total protein signals quantified by immunoblotting described in Fig 3. Ratios of p-PERK/t-PERK (top) and p-eIF2α/ t-eIF2α (bottom) are indicated in Tables (mean ± SD). Although differences were not statistically significant, p-PERK/t-PERK ratios tended to be higher in prion-infected CxNs and ThNs than mock-infected CxNs and ThNs. In contrast to ratios of p-PERK/t-PERK, those of p-eIF2α/t-eIF2α did not differ between prion-infected and mock-infected primary neurons.

    (TIF)

    S4 Fig. Immunostaining for p-PERK (Thr980) using a rabbit monoclonal antibody (16F8) in tunicamycin-treated Neuro2a cells.

    Immunofluorescence staining for p-PERK (green) with counter staining for nuclei (DAPI, blue) was carried out using Neuro2a cell treated with tunicamycin at indicated concentrations for 12 hrs. Images are shown as maximum intensity projection created from z-series stacks of confocal images. Fluorescent granular signals stained by this antibody appeared more in tunicamycin-treated Neuro2a cells (5.0 μg/ml) than in untreated Neuro2a cells, indicating that the specificity of reaction of this antibody in IFA. Bars, 10 μm.

    (TIF)

    S5 Fig. Phosphorylation of PERK in PrPSc-positive thalamic neurons.

    (A) Multiple immunofluorescence staining for p-PERK and PrPSc with counter staining for MAP2 and nuclei (DAPI) in ThNs at 21 dpi. PrPSc was stained with mAb 8D5. Figures are shown as maximum intensity projection images. Arrows indicate a PrPSc++ neuron. Bars, 50 μm. (B, C) Quantification of p-PERK and PrPSc in individual neurons by 3D-image analysis using Imaris software. Each dot in the scatter diagram (B) represents an individual thalamic neuron although some neurons were spotted at the same position (r, correlation coefficient). In (C), Obihiro-infected ThN was analyzed as a whole (Obihiro) and as three subpopulations classified by the frequency of PrPSc signals at the soma. The definition of the three subpopulations and the number of cells used for this analysis are as follows: PrPSc_low (< 4 PrPSc signals/cell, n = 49), PrPSc+ (≥ 4 PrPSc signals/cell, n = 26, including PrPSc++), and PrPSc++ (≥ 13 PrPSc signals/cell, n = 12). The number of cells in mock-infected ThN and Obihiro-infected ThN used for the analysis are n = 49 and n = 75, respectively. Differences between the groups were analyzed by Steel-Dwass’s multiple comparison tests. *, p < 0.05

    (TIF)

    S1 Raw images

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers_0503_MT.pdf

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES